PCM
BPMC

Peregrine Capital Management’s Blueprint Medicines BPMC Stock Holding History

Peregrine Capital Management’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-96,149
Closed -$8.51M – 333
2025
Q1 		$8.51M Sell
96,149
-2,663
-3% -$260K 0.28% 92
2024
Q4 		$8.62M Buy
98,812
+1,761
+2% +$161K 0.26% 104
2024
Q3 		$8.98M Buy
97,051
+17,491
+22% +$1.74M 0.27% 87
2024
Q2 		$8.57M Sell
79,560
-14,023
-15% -$1.4M 0.25% 108
2024
Q1 		$8.88M Buy
93,583
+1,810
+2% +$155K 0.25% 104
2023
Q4 		$8.47M Sell
91,773
-54,890
-37% -$3.56M 0.25% 119
2023
Q3 		$7.37M Buy
146,663
+3,074
+2% +$164K 0.22% 183
2023
Q2 		$9.07M Sell
143,589
-16,015
-10% -$871K 0.25% 153
2023
Q1 		$7.18M Buy
159,604
+31,362
+24% +$1.41M 0.21% 210
2022
Q4 		$5.62M Buy
128,242
+15,954
+14% +$765K 0.18% 225
2022
Q3 		$7.4M Sell
112,288
-20,333
-15% -$1.31M 0.24% 193
2022
Q2 		$6.7M Buy
132,621
+5,753
+5% +$337K 0.2% 222
2022
Q1 		$8.1M Buy
126,868
+3,199
+3% +$230K 0.19% 216
2021
Q4 		$13.2M Buy
123,669
+3,500
+3% +$366K 0.27% 124
2021
Q3 		$12.4M Sell
120,169
-39,414
-25% -$3.67M 0.26% 155
2021
Q2 		$14M Buy
159,583
+8,471
+6% +$776K 0.25% 182
2021
Q1 		$14.7M Sell
151,112
-21,086
-12% -$2.11M 0.27% 179
2020
Q4 		$19.3M Sell
172,198
-15,651
-8% -$1.65M 0.37% 90
2020
Q3 		$17.4M Buy
187,849
+17,742
+10% +$1.37M 0.46% 75
2020
Q2 		$13.3M Sell
170,107
-28,360
-14% -$1.92M 0.38% 107
2020
Q1 		$11.6M Buy
+198,467
New +$12.8M 0.42% 100

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Peregrine Capital Management's BPMC Position: Q2 2025 in Review

Peregrine Capital Management sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 96,149 shares — an estimated $8.51M sold.

Peregrine Capital Management first reported a position in BPMC in Q1 2020 and held it in 21 quarters. The position peaked at $19.3M in Q4 2020. 354 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Peregrine Capital Management reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Peregrine Capital Management sold 96,149 Blueprint Medicines shares in Q2 2025, an estimated $8.51M.
  • Peregrine Capital Management first reported a position in Blueprint Medicines in Q1 2020 and held it in 21 quarters.
  • Peregrine Capital Management's Blueprint Medicines position peaked at $19.3M in Q4 2020.
  • 354 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Peregrine Capital Management's 13F filing for Q2 2025, filed 1 Aug 2025.